Skip to navigation Skip to content

Hereditary angioedema (HAE) type 1 or type 2 Program in Pharmaceutical Benefits Scheme (PBS) 012-21112939

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised lanadelumab for patients with hereditary angioedema (HAE) type 1 or 2.

HAE type 1 or 2 and listing dates

HAE is a rare inherited disorder characterised by recurrent episodes of severe swelling (angioedema) mainly in the limbs, face, intestinal tract or airway.

Listing date: lanadelumab - 01 December 2021.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority approval requests

Written Authority Required Drugs